# OnCo record elvn-002 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/elvn-002/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "elvn-002" ;
  schema:name "ELVN-002"@en ;
  schema:description "ELVN-002 is an experimental oral small-molecule kinase inhibitor from Enliven Therapeutics, in phase 1 trials for HER2-mutant non-small cell lung cancer, HER2-positive breast cancer and HER2-positive gastric and colorectal cancer; development is paused."@en ;
  schema:url <https://onco.cc/drugs/elvn-002/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.enliventherapeutics.com/pipeline>, <https://www.enliventherapeutics.com/pipeline>, <https://clinicaltrials.gov/search?intr=ELVN-002> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral small-molecule kinase inhibitor (irreversible)" ;
  onco:cancers <https://onco.cc/cancers/her2-mutant-nsclc/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/colorectal/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/enliven-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct05650879/>, <https://onco.cc/trials/nct06328738/> .